SH006

Phase 3Small molecule

NNanjing Sanhome Pharmaceutical, Co., Ltd.

SH006 is one of 73 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaNot yet recruiting

Patients With Advanced Solid TumorsActive, not recruiting

Hepatocellular CarcinomaPhase 3

Not yet recruiting

Patients With Advanced Solid TumorsPhase 1

Active, not recruiting

Competition

Competitive Landscape

251 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

SH006

NNanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 3

1 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Doptelet

AAkarx

Preclinical

1 8

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 9

Vermox

WWim Janssens

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Active, not recruiting

Patients With Advanced Solid Tumors

NCT07362264

Q1 2030

Phase 2/3Not yet recruiting

Hepatocellular Carcinoma

NCT07392866

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors

Active, not recruiting·NNanjing Sanhome Pharmaceutical, Co., Ltd.·Phase 1·NCT07362264·50 enrolled

Hepatocellular Carcinoma1 trial

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Not yet recruiting·NNanjing Sanhome Pharmaceutical, Co., Ltd.·Phase 2/3·NCT07392866·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SH006. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SH006 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SH006. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanjing Sanhome Pharmaceutical, Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNanjing Sanhome Pharmaceutical, Co., Ltd.

SH006

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2030

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News